Glycyrrhizin
![]() |
|
![]() |
|
Systematic (IUPAC) name | |
---|---|
(3β,20β)-20-carboxy-11-oxo-30-norolean-12-en-3-yl 2-O-β-D-glucopyranuronosyl-α-D-glucopyranosiduronic acid
|
|
Clinical data | |
Trade names | Epigen, Glycyron |
AHFS/Drugs.com | International Drug Names |
Legal status |
|
Routes of administration |
Oral, intravenous |
Pharmacokinetic data | |
Metabolism | Hepatic and by intestinal bacteria |
Biological half-life | 6.2-10.2 hours[1] |
Excretion | Faeces, urine (0.31-0.67%)[2] |
Identifiers | |
CAS Number | 1405-86-3 (α-D-Glucopyranosiduronic acid), Template:CAS (β-D-Glucopyranosiduronic acid) |
ATC code | A05BA08 (WHO) |
PubChem | CID: 128229 |
ChemSpider | 14263 ![]() |
UNII | 6FO62043WK |
ChEBI | CHEBI:15939 ![]() |
ChEMBL | CHEMBL441687 ![]() |
Chemical data | |
Formula | C42H62O16 |
Molecular mass | 822.93 g/mol |
|
|
|
|
Physical data | |
Solubility in water | 1-10 mg/mL (20 °C) |
Glycyrrhizin (or glycyrrhizic acid or glycyrrhizinic acid) is the chief sweet-tasting constituent of Glycyrrhiza glabra (liquorice) root. Structurally it is a saponin and has been used as an emulsifier and gel-forming agent in foodstuff and cosmetics. Its aglycone is enoxolone and it has therefore been used as a prodrug for that compound, for example it is used in Japan to prevent liver carcinogenesis in patients with chronic hepatitis C.[3]
Contents
Medical uses
Glycyrrhizin inhibits liver cell injury and is given intravenously for the treatment of chronic viral hepatitis and cirrhosis in Japan.[4][5] It has also proven itself effective in the treatment of autoimmune hepatitis in one clinical trial.[6]
Adverse effects
The most widely reported side effects of glycyrrhizin use are fluid retention. These effects are related to the inhibition of cortisol metabolism within the kidney, and the subsequent stimulation of the mineralocorticoid receptors.[7] Other side effects include:[8]
<templatestyles src="Div col/styles.css"/>
- Headache
- Paralysis
- Transient visual loss
- Torsades de pointes
- Tachycardia
- Cardiac arrest
- Hypokalaemia
- Reduced testosterone
- Premature birth
- Acute kidney failure
- Muscle weakness
- Myopathy
- Myoglobinuria
- Rhabdomyolysis
- Increased body weight
Mechanism of action
It inhibits the enzyme 11beta-hydroxysteroid dehydrogenase, which likely contributes to its anti-inflammatory and mineralocorticoid activity.[8] It has a broad-spectrum of antiviral activity in vitro against:[8][9]
<templatestyles src="Div col/styles.css"/>
- Herpes simplex virus,[10] which has also been confirmed in vivo.[11]
- Influenzavirus (including H5N1)[12]
- Varicella zoster virus[13]
- SARS coronavirus
- HIV
- Hepatitis A virus
- Hepatitis B virus
- Hepatitis C virus
- Hepatitis E virus
- Epstein-barr virus
- Human cytomegalovirus
- Flavivirus
- Japanese encephalitis virus
Pharmacokinetics
After oral ingestion, glycyrrhizin is first hydrolysed to 18β-glycyrrhetinic acid by intestinal bacteria. After complete absorption from the gut, β-glycyrrhetinic acid is metabolised to 3β-monoglucuronyl-18β-glycyrrhetinic acid in the liver. This metabolite then circulates in the bloodstream. Consequently its oral bioavailability is poor. The main part is eliminated by bile and only a minor part (0.31–0.67%) by urine.[14] After oral ingestion of 600 mg of glycyrrhizin the metabolite appeared in urine after 1.5 to 14 hours. Maximal concentrations (0.49 to 2.69 mg/l) were achieved after 1.5 to 39 hours and metabolite can be detected in the urine after 2 to 4 days.[14]
Organoleptic properties
It is 30-50 times as sweet as sucrose (table sugar).[8][15]
See also
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references>
tag; parameter "group" is allowed only.
<references />
, or <references group="..." />
External links
- CHEMICAL MODIFICATION OF GLYCYRRHIZIC ACID AS A ROUTE TO NEW BIOACTIVE COMPOUNDS FOR MEDICINE by L.A.Baltina; doi:10.2174/0929867033368538
Script error: The function "top" does not exist.
Script error: The function "bottom" does not exist.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ 8.0 8.1 8.2 8.3 Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ 14.0 14.1 Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- Pages with reference errors
- Chemical articles having calculated molecular weight overwritten
- Infobox drug articles without a structure image
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles containing unverified chemical infoboxes
- Pages using div col with unknown parameters
- Pages using navboxes with unknown parameters
- Triterpene glycosides
- Sugar substitutes
- Saponins
- 11β-HSD inhibitors